Johnson & Johnson (FRA:JNJ) FFO


FRA:JNJ Johnson & Johnson FRA:JNJ
81 GF Score
Price €234.80
GF Value €167.80
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson FFO?

FFO (Funds from operations) only applies to REITs.

FRA:JNJ
81GF Score
Johnson & Johnson FRA:JNJ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (FRA:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of €234.80 is trading 39.9% above its estimated GF Value™ of €167.80. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for FRA:JNJ:

  • FFO:
  • GF Value™: €167.80 vs. price of €234.80 (39.9% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the FRA:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
81GF Score

Get the complete analysis for FRA:JNJ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€234.80
Price
€167.80
GF Value